Arthritis Clinic and Research Center, Peking University People's Hospital, Beijing, 100044, People's Republic of China.
Institute of Sports Medicine, Peking University Third Hospital, Beijing, 100044, People's Republic of China.
J Orthop Surg Res. 2020 Mar 30;15(1):120. doi: 10.1186/s13018-020-01617-6.
Matrix-associated autologous chondrocyte implantation (MACI) achieves good clinical efficacy in young patients with focal cartilage injury; however, phenotypic de-differentiation of chondrocytes cultured in monolayer and the treatment of older OA patients are still challenges in the field of cartilage tissue engineering. This study aimed to assess the in vitro re-differentiation potential and in vivo chondrogenic capacity of human OA chondrocytes inoculated into collagen I scaffolds with different cellular phenotypes and seeding densities.
OA chondrocytes and articular chondrocyte-laden scaffolds were cultured over 2 weeks in in vitro. Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) and histological staining were used to detect the mRNA expression profiles and extracellular matrix secretion of chondrocyte-specific markers. OA chondrocyte-laden collagen I scaffolds with different cellular phenotypes, and seeding densities were implanted into SCID mice over 4 weeks to evaluate the chondrogenic capacity in vivo.
Increased COL2a1, ACAN, COMP, SOX9, and BMP2 expression levels and decreased COL1a1, VCAN, MMP13, and ADAMTS5 amounts were observed in OA chondrocytes seeded in collagen I scaffolds; Implantation of phenotypically superior OA chondrocytes in collagen I scaffolds at high density could improve the chondrogenic capacity of human OA chondrocytes, as confirmed by RT-qPCR assessed gene expression patterns in vitro and histological evaluation in vivo.
Freshly isolated chondrocytes from OA patients could be a source of replacement for articular chondrocytes being commonly used in MACI. Implantation of phenotypically superior OA chondrocytes in collagen I scaffolds at high density could be a promising tool for the treatment of elderly OA patients.
基质相关自体软骨细胞植入(MACI)在年轻的局灶性软骨损伤患者中具有良好的临床疗效;然而,在单层培养的软骨细胞中出现表型去分化以及治疗老年 OA 患者仍然是软骨组织工程领域的挑战。本研究旨在评估接种在不同细胞表型和接种密度的胶原 I 支架中的人 OA 软骨细胞的体外再分化潜力和体内软骨形成能力。
OA 软骨细胞和关节软骨细胞负载的支架在体外培养 2 周。逆转录定量聚合酶链反应(RT-qPCR)和组织学染色用于检测软骨细胞特异性标志物的 mRNA 表达谱和细胞外基质分泌。将具有不同细胞表型和接种密度的 OA 软骨细胞负载的胶原 I 支架植入 SCID 小鼠体内 4 周,以评估体内的软骨形成能力。
在胶原 I 支架中接种的 OA 软骨细胞中观察到 COL2a1、ACAN、COMP、SOX9 和 BMP2 的表达水平增加,COL1a1、VCAN、MMP13 和 ADAMTS5 的含量减少;在高浓度胶原 I 支架中接种表型优越的 OA 软骨细胞可提高人 OA 软骨细胞的软骨形成能力,这通过体外 RT-qPCR 评估基因表达模式和体内组织学评估得到证实。
新鲜分离的 OA 患者软骨细胞可以替代 MACI 中常用的关节软骨细胞。在高浓度胶原 I 支架中接种表型优越的 OA 软骨细胞可能是治疗老年 OA 患者的一种有前途的工具。